This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of~~ A method for preventing or treating hyperuricemia and/or one or several associated disorders or diseases, and/or ~~for~~ reducing the serum uric acid level of a subject, comprising administering to a subject in need thereof a compound of formula (I).



(I)

in which:

X ~~represents~~ is O or S;

A ~~represents either the~~ is a divalent radical

$-(CH_2)_s-CO-(CH_2)_t-$ or ~~the divalent radical~~ $-(CH_2)_s-CR_3R_4-(CH_2)_t-$,

in which ~~radicals~~ s = t = 0 or ~~else~~ one of s and t has the value 0 and the other has the value 1;

~~R_4 represents a hydrogen atom or a (C_1-C_{15})alkyl group;~~

R_1 and R_2 are, each independently, ~~represent the~~ Z ~~chain defined below~~; a hydrogen atom; a (C_1-C_{18})alkyl group; a (C_2-C_{18})alkenyl group; a (C_2-C_{18})alkynyl group; a (C_6-C_{10})aryl group optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group; or a mono- or bicyclic (C_4-C_{12})heteroaryl group ~~comprising~~ containing one or more ~~heteroatoms chosen from~~ O, N ~~and~~ and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group;

R_3 and R_4 are, each independently, ~~takes any one of the meanings given above for R_1 and R_2, with the exception of the Z chain~~ a hydrogen atom; a (C_1-C_{18})alkyl group; a (C_2-C_{18})alkenyl group; a (C_2-C_{18})alkynyl group; a (C_6-C_{10})aryl group optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group; or a mono- or bicyclic (C_4-C_{12})heteroaryl group containing one or more O, N and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group; or

R_3 and R_4 together form a (C_2-C_6)alkylene chain optionally substituted by a halogen atom or by optionally halogenated (C_1-C_5)alkoxy;

R is ~~chosen from~~ a halogen atom; a cyano group; a nitro group; a carboxy group; an optionally halogenated (C_1-C_{18})alkoxycarbonyl group; an R_a-CO-NH- or R_aR_bN-CO- group; ~~[in which R_a and R_b independently represent optionally halogenated (C_1-C_{18})alkyl; a hydrogen atom; (C_6-C_{10})aryl or (C_6-C_{10})aryl(C_1-C_5)alkyl (where the aryl parts are optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group); (C_3-C_{12})cycloalkyl optionally substituted by a halogen atom, by an optionally halogenated C_1-C_5 alkyl [sic] group or by an optionally halogenated (C_1-C_5)alkoxy group];~~ an optionally halogenated (C_1-C_{18})alkyl group; optionally halogenated (C_1-C_{18})alkoxy; and (C_6-C_{10})aryl, (C_6-C_{10})aryl(C_1-C_5)alkyl, (C_6-C_{10})aryloxy, (C_3-C_{12})cycloalkyl, (C_3-C_{12})cycloalkenyl, (C_3-C_{12})cycloalkyloxy or (C_3-C_{12})cycloalkenyloxy, in which the aryl, cycloalkyl ~~and~~ or cycloalkenyl ~~parts are~~ group is optionally substituted by a halogen atom, by optionally halogenated (C_1-C_5)alkyl or by an optionally halogenated (C_1-C_5)alkoxy; -OH;

R_a and R_b are, each independently, an optionally halogenated (C_1-C_{18})alkyl; a hydrogen atom; (C_6-C_{10})aryl or (C_6-C_{10})aryl(C_1-C_5)alkyl, in which the aryl group is optionally

substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group); (C_3-C_{12})cycloalkyl optionally substituted by a halogen atom, by an optionally halogenated C_1-C_5 alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group;

p ~~represents~~ is 0, 1, 2, 3 or 4;

Z ~~represents the radical~~ is:



~~where~~

n is 1 or 2;

~~the~~ R' ~~groups~~ are, each independently, ~~represent~~ a hydrogen atom; a (C_1-C_5)alkyl group; a (C_6-C_{10})aryl group optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by optionally halogenated (C_1-C_5)alkoxy; or a mono- or bicyclic (C_4-C_{12})heteroaryl group ~~comprising one or more heteroatoms chosen from~~ containing one or more O, N ~~and~~ and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group;

Y ~~represents~~ is -OH; (C_1-C_5)alkoxy; or ~~the~~ -NR_cR_d; ~~group (in which~~

or glucomic acid



R_c and R_d are, each independently, ~~represent~~ a hydrogen atom; $(C_1$-$C_5)$alkyl; $(C_3$-$C_8)$cycloalkyl optionally substituted by a halogen atom, by optionally halogenated $(C_1$-$C_5)$alkyl or by optionally halogenated $(C_1$-$C_5)$alkoxy; $(C_6$-$C_{10})$aryl optionally substituted by a halogen atom, by optionally halogenated $(C_1$-$C_5)$alkyl or by optionally halogenated $(C_1$-$C_5)$alkoxy;

~~Or Y represents glucomic acid~~



~~it being understood that~~

wherein one, and one alone, ~~from~~ of R_1 and R_2 ~~represents the~~ is ~~Z chain;~~

~~and their~~ or a pharmaceutically acceptable ~~salts with acids or bases, or esters~~ salt thereof with a acid or base, or an ester thereof.

2. (Currently Amended) ~~The use~~ A method according to Claim 1, ~~characterized in that~~ wherein A ~~represents~~ is the divalent radical $-(CH_2)_s-CR_3R_4-(CH_2)_t-$ ~~in which s, t, R_3 and R_4 are as defined in Claim 1~~.

3. (Currently Amended) ~~The use~~ A method according to Claim 1, ~~characterized in that:~~

X ~~represents~~ is O;

A ~~represents~~ is $-CR_3R_4-$ or $-CH_2-CR_3R_4-$, in which the unsubstituted methylene group

is bonded to X;

R_1 and R_2 are, each independently, ~~represent~~ Z; H; (C_1-C_{15})alkyl; (C_2-C_{15})alkenyl; or phenyl optionally substituted by (C_1-C_5)alkyl, (C_1-C_5)alkoxy, a halogen atom or -CF_3;

R_3 and R_4 are, each independently, a hydrogen atom; a (C_1-C_{18})alkyl group; a (C_2-C_{18})alkenyl group; a (C_2-C_{18})alkynyl group; a (C_6-C_{10})aryl group optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group; or a mono- or bicyclic (C_4-C_{12})heteroaryl group containing one or more O, N and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated (C_1-C_5)alkyl group or by an optionally halogenated (C_1-C_5)alkoxy group;

~~takes any one of the meanings given above for R_1 and R_2, with the exception of Z;~~

R is ~~chosen from~~ (C_1-C_9)alkyl; (C_1-C_5)alkoxy; phenyl or phenylcarbonyl optionally substituted by a halogen atom, (C_1-C_5)alkyl, (C_1-C_5)alkoxy, -CF_3 or -OCF_3; a halogen atom; -CF_3 ~~and~~ or -OCF_3;

~~Z represents the radical:~~



~~where~~ n ~~represents~~ is 1; and

R' ~~represents~~ is (C_1-C_5)alkyl or (C_6-C_{10})aryl.

4. (Currently Amended) ~~The use~~ A method according to claim 1, wherein~~:~~

X ~~represents~~ is O;

A ~~represents~~ is -CH_2-CR_3R_4-, in which the unsubstituted methylene group is bonded

to X;

R_1 and R_2 are, each independently, ~~represent~~ Z, a hydrogen atom or $(C_1$-$C_5)$alkyl;

R_3 and R_4 are, each independently, a hydrogen atom; a $(C_1$-$C_{18})$alkyl group; a $(C_2$-$C_{18})$alkenyl group; a $(C_2$-$C_{18})$alkynyl group; a $(C_6$-$C_{10})$aryl group optionally substituted by a halogen atom, by an optionally halogenated $(C_1$-$C_5)$alkyl group or by an optionally halogenated $(C_1$-$C_5)$alkoxy group; or a mono- or bicyclic $(C_4$-$C_{12})$heteroaryl group containing one or more O, N and/or S atoms, which is optionally substituted by a halogen atom, by an optionally halogenated $(C_1$-$C_5)$alkyl group or by an optionally halogenated $(C_1$-$C_5)$alkoxy group;

~~takes any one of the meanings given above for R_1 and R_2, with the exception of Z;~~

Z ~~represents~~ is



; and

R' ~~represents~~ is methyl or phenyl.

5. (Currently Amended) ~~The use~~ A method according to claim 1, wherein ~~R1 represents~~ R_1 is Z.

6. (Currently Amended) ~~The use~~ A method according to claim 1, wherein R_2 ~~represents~~ is a hydrogen atom.

7. (Currently Amended) ~~The use~~ A method according to claim 1, wherein Y is a $(C_1$-$C_5)$ alkoxy.

8. (Currently Amended) ~~The use~~ A method according to claim 1, wherein~~:~~

Y ~~represents~~ is -OH; (C_1-C_5)alkoxy; or -NR_cR_d ~~in which R_c and R_d are as defined in Claim 1~~.

9. (Currently Amended) ~~The use~~ A method according to claim 1, wherein R' is methyl.

10. (Currently Amended) ~~The use~~ A method according to claim 1, wherein R is (C_1-C_5) alkoxy.

11. (Currently Amended) ~~The use~~ A method according to claim 1, wherein p ~~represents~~ is 0, 1 or 2.

12. (Currently Amended) ~~The use~~ A method according to claim 1, wherein~~:~~

~~[X represents~~

X is O ;

A ~~represents~~ is $-CH_2-CR_3R_4-$, in which the unsubstituted methylene group is bonded to X ;

R_1 is Z and R_2 is H;

R_3 and R_4 are, each independently, ~~represents a~~ (C_1-C_5) alkyl ~~group~~;

R is a (C_1-C_5) alkoxy;

Z ~~represents~~ is



;

~~wherein~~ R' ~~represents a~~ is methyl or phenyl ; and

Y is $(C_1$-$C_5)$alkoxy ~~y represents a $(C_1$-$C_5)$alkoxy~~.

13. (Currently Amended) ~~The use~~ A method according to claim 1, wherein ~~said derivative is selected from the group consisting of~~ the compound of formula (I) is

- (2E, 4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2,2-dimethyl-6-methoxy-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2,2-dimethyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(2,2-dimethyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-[2-(non-6-enyl)-2H-1-benzopyran-3-yl]-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(4-phenyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(6-nonyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(6-phenyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2-nonyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(4-methyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2-undecanyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2-phenyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(5-methyl-2,3-dihydrobenzoxepin-4-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid; and
- (2E, 4E)-5-(2,3-dihydrobenzoxepin-4-yl)-3-methylpenta-2,4-dienoic acid;

- (2E, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-phenylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-phenylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7,8-dimethoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-2,3-dihydro-7-(para-chlorobenzoyl)benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-chloro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7,8-dichloro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-bromo-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-fluoro-8-chloro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-fluoro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-trifluoromethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;

– (2E, 4E)-5-(3,3-dimethyl-7-phenyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;

– (2E, 4E)-5-(3,3,7-trimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;

– (2E, 4E)-5-(3,3-dimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid; or

– (2E, 4E)-5-(9-methoxy-3,3-dimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;

~~and their~~ or a pharmaceutically acceptable ~~esters~~ ester thereof.

14. (Currently Amended) ~~The use~~ A method according to claim 1, wherein ~~the diseases associated with hyperuricemia to be treated comprise one or several of the following~~ : gout, acute inflammatory arthritis, tophaceous deposition of urate crystals in and around joints, chronic arthritis, deposition of urate crystals in renal parenchyma, urolithiasis, ~~and~~ or a related renal disease ~~also termed~~ or gouty nephropaty is treated.

15. (Currently Amended) ~~The use~~ A method according to claim 1, wherein ~~the hyperuricemiae to be treated comprises~~ primary ~~and~~ or secondary hyperuricemiae, ~~such as drug related to hyperuricemiae (e.g. by diuretics, immunosuppressive of cytotoxic agents),~~ or hyperuricemiae related to ~~diverse medical conditions (e.g.~~ nephropaties, a myeloproliferative disorder, a condition ~~disorders, conditions~~ associated with insuline resistance ~~and~~ or transplantation is treated ~~transplantations)~~.

16. (Currently Amended) ~~The use~~ A method according to claim 1, wherein the subject has a ~~to prepare medicaments for subjects having~~ serum uric acid ~~levels~~ level, before treatment, equal or above 7 mg/dL (420 %m/L).

17. (Currently Amended) ~~The use~~ A method according to claim 16, wherein ~~where the conditions to be treated are~~ gout or ~~any~~ a condition brought about by a high ~~levels~~ level of uric acid in the joints or kidneys or a serum level over 9 mg/dL (530μ mol/L) is treated.

18. (Currently Amended) ~~The use~~ A method according to claim 1, wherein the administration is by ~~for preparing a medicament suitable for administering the 2,4-pentadienoic acid derivative of formula (I) by the~~ oral route.

19. (Currently Amended) ~~The use~~ A method according to claim 1, wherein the administration is ~~for preparing a medicament for administering the effective amount of 2,4-pentadienoic acid or derivative according to formula (I)~~ once or twice per day.

20. (Currently Amended) ~~The use~~ A method according to claim 1, wherein the amount of ~~said pentadienoic acid derivative is substantially~~ a compound of formula (I) administered is lower than the amount ~~needed for the relevant derivative as~~ used in the treatment of dyslipidemia, atherosclerosis ~~and~~ or diabetes.

21. (Currently Amended) ~~The use~~ A method according to claim 20, wherein said amount is at least 50% lower.

22. (Currently Amended) ~~The use~~ A method according to claim 21, wherein said amount is at least 90% lower.

23. (Currently Amended) ~~The use~~ A method according to claim 1, wherein the amount of ~~said pentadienoic acid derivative is from~~ a compound of formula (I) administered

is 0.15 to 4 mg/Kg of human body weight.

24. (Currently Amended) ~~The use~~ A method according to claim 23, wherein said amount is ~~from~~ 0.3 to 1.0 mg/Kg human body weight.

25. (Currently Amended) ~~The use~~ A method according to claim 1, wherein ~~said derivative is~~ (2E,4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzo-xepin-5-yl)-3-methylpenta-2,4-dienoic acid, or ~~its~~ a pharmaceutically acceptable ~~salts or esters, among which its ethyl ester~~ salt or ester thereof is administered.

26-33. (Cancelled)

34. (New) A method according to claim 1, wherein an ethyl ester of (2E,4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzo-xepin-5-yl)-3-methylpenta-2,4-dienoic acid is administered.

35. (New) A method according to claim 1, wherein R_4 is a hydrogen atom or a (C_1-C_{15})alkyl group.

36. (New) A method according to claim 1, wherein a compound of formula I or a pharmaceutically acceptable salt thereof is administered.

37. (New) A method according to claim 1, wherein the compound of formula (I) is

– (2E, 4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;

- (2Z, 4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2,2-dimethyl-6-methoxy-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2,2-dimethyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(2,2-dimethyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-[2-(non-6-enyl)-2H-1-benzopyran-3-yl]-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(4-phenyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(6-nonyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(6-phenyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2-nonyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(4-methyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2-undecanyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(2-phenyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(5-methyl-2,3-dihydrobenzoxepin-4-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid; and
- (2E, 4E)-5-(2,3-dihydrobenzoxepin-4-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-phenylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-phenylpenta-2,4-dienoic acid;
- (2Z, 4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;

- (2E, 4E)-5-(3,3-dimethyl-7,8-dimethoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-2,3-dihydro-7-(para-chlorobenzoyl)benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-chloro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7,8-dichloro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-bromo-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-fluoro-8-chloro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-fluoro-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-trifluoromethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-7-phenyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3,7-trimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;
- (2E, 4E)-5-(3,3-dimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid; or
- (2E, 4E)-5-(9-methoxy-3,3-dimethyl-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid;

or a pharmaceutically acceptable salt thereof.